GeneDx Holdings Corp. (WGS)
| Market Cap | 2.66B +29.2% |
| Revenue (ttm) | 402.19M +50.5% |
| Net Income | 2.08M |
| EPS | 0.07 |
| Shares Out | 28.90M |
| PE Ratio | 1,236.21 |
| Forward PE | 210.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 296,180 |
| Open | 90.70 |
| Previous Close | 91.03 |
| Day's Range | 89.84 - 93.23 |
| 52-Week Range | 55.17 - 170.87 |
| Beta | 2.02 |
| Analysts | Strong Buy |
| Price Target | 138.13 (+50.32%) |
| Earnings Date | Feb 23, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Financial Performance
In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $138.13, which is an increase of 50.32% from the latest price.
News
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health
GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.
Polen 5Perspectives Small Growth Portfolio Performance & Attribution
The Portfolio returned -1.3% gross and -1.5% net compared to the 1.2% return of the Russell 2000 Growth Index. Bloom Energy announced better than expected results with added optimism from a $5B partne...
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026.
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties...
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum
GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exc...
Why is GeneDx stock crashing on Monday?
GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that inves...
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.
GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--Dr. Linda Genen named CMO to further strengthen GeneDx's commitment to delivering earlier answers and better outcomes through genomic insights.
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced a record-setting year for its research programs, reinforcing its position as the global leader in rare disease genomics.
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco.
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year
GAITHERSBURG, Md.--(BUSINESS WIRE)--The GUARDIAN study has been recognized as one of the most impactful scientific contributions published across all JAMA journals this year.
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of...
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming...
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial...
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.
GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement...
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whe...
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.